For how we live.
9 articles published between December 16, 2025 and October 14, 2026.
In the 17,701-person E.mbrace trial in adults 60 and older, the nine-valent ExPEC9V vaccine showed 14.63% efficacy, with a confidence interval spanning zero. It stopped early for futility; development is discontinued.
Urinary infections in men were long treated as automatically complicated. A randomised trial found seven days of antibiotics non-inferior to fourteen, and guidelines say not to treat urine that causes no symptoms.
Fever is often the only clue in a young child, a properly collected urine sample confirms it, and most cases clear on a short antibiotic course. Preventive antibiotics cut recurrences but breed resistant bugs.
A short course of a first-line antibiotic clears most uncomplicated UTIs. Five-day nitrofurantoin beat single-dose fosfomycin (70% vs 58% resolution), and two-thirds of women recovered on ibuprofen alone.
A Cochrane review of 50 trials found cranberry products lower UTI risk in women with recurrent infections and in children, but no benefit in the elderly, in pregnancy, or in bladder-emptying problems.
In the 240-woman ALTAR trial, methenamine hippurate was non-inferior to standard low-dose antibiotic prophylaxis over a year. Most other non-antibiotic prevention strategies still rest on weak evidence.
Maccabi Healthcare Services studied 626 of its own physicians to work out who follows algorithmic prescribing advice — and found the pattern was about practice structure, not just attitude.
In the phase 3 Integral-1 trial, cefepime plus the new β-lactamase blocker nacubactam cured 82% of complicated urinary infections versus 61% for imipenem, offering a way to spare carbapenems.
A study of 1.8 million Medicare beneficiaries found vaginal estrogen prescriptions went unfilled by the overwhelming majority — and were least likely of all in women with recurrent urinary tract infections.